WuXi Biologics rises more than 6%! For a license-out deal with GSK

【Pharmaceutical Network Pharmaceutical Stock Market】News on January 5, CRO head company WuXi Biologics opened more than 3%.

As of 9:42, the stock was up more than 6%, or 6.
65%, at HK$70.
6, with a turnover of 526 million, a turnover rate of 0.
18%, and a price-to-earnings (TTM) of 62.
46
.
On January 5, WuXi Biologics announced that it has entered into a license-out deal with GSK under which GSK will acquire exclusive global research, development, manufacturing and commercialization rights for one preclinical bispecific antibody and up to three other TCE antibodies in the early stage of early discovery
.
It is reported that the bispecific antibody targets tumor-associated antigen (TAA) and T cell surface antigen CD3 on the surface of tumor cells, respectively, and specifically activates T cells by binding to tumor cells and T cells, thereby killing tumor cells and producing anti-tumor activity
.
Through this transaction, WuXi Biologics will receive an upfront payment of US$40 million and research, development, registration and commercialization milestones for four TCE antibodies of up to US$1.
46 billion
.
WuXi Biologics is also eligible for a tiered sales commission
based on net sales.
It is understood that bispecific antibodies can specifically bind two antigens or one antigen different epitopes at the same time, through its mode of action, can achieve the function that monospecific antibodies can not achieve, and is expected to solve the potential problems such as single-target drug resistance and insufficient safety, the current global bispecific antibody overall research and development is early, but its importance and future space have been widely recognized by the market, attracting many multinational pharmaceutical companies layout
.
In China, the bispecific antibody layout is also very hot, a number of local companies have self-developed bi-antibody technology platforms, currently under research pipelines up to hundreds, and the potential of domestic technology platforms has been recognized
by international pharmaceutical companies.
The cooperation between WuXi Biologics and GSK also proves that WuXi Biologics' Best-in-Class CD3 antibody technology platform and dual antibody technology platform WuXiBody® have been recognized
by each other.
It is reported that the license agreement between GSK and WuXi Biologics will further expand the company's tumor targeted drug portfolio, meet the huge unmet medical needs, and provide potential treatment options
for cancer patients with multiple types of cancer.
As a leading CRO company in China, WuXi Biologics' biopharmaceutical capabilities and technology enablement platform have been recognized
by multinational pharmaceutical companies more than once.
In April 2020, WuXi Biologics announced that it has signed a strategic collaboration agreement with U.
S.
biotech company Aravive to license Aravive to develop high-affinity bispecific antibodies for the treatment of cancer and fibrotic diseases
using WuXiBody, an innovative technology platform.
Under the partnership, WuXi Biologics will provide antibody discovery, process development and manufacturing services, while Aravive will be responsible for preclinical and clinical development
.
In addition to WuXi Biologics, companies with self-developed bispecific antibody technology platforms such as Harbour Biologics have also received hundreds of millions of dollars in transactions
through external licensing and cooperation.
For example, in April 2020, Harbour Pharma entered into an HBM7022 global licensing agreement with AstraZeneca, which will receive an upfront payment of US$25 million and a milestone payment of up to US$325 million and royalties
for net sales.
It is reported that HBM7022 is the first domestic "going to sea" bispecific antibody product, which is a new Claudin18.
2x CD3 bi-antibody generated based on the HBICE platform of Harbour Pharmaceutical, which can activate T cells and kill tumor cells by binding tumor cells and T cells, and is still in the preclinical stage
.
Its unique "2+1" structure can not only provide better tumor selectivity and expand the treatment window, but also reduce the risk of
cytokine storm while ensuring high lethality.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.